Takeda Delivers Strong FY2021 Results; Continued Growth Mome

11.05.2022 - Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the performance of its growth products, new product launches and strength across its key business areas. Takeda ...

Related Keywords

Japan , China , United States , Russia , Ukraine , Willebrand , Nordrhein Westfalen , Germany , Japanese , , Exchange Commission , Federal Reserve Bank , International Financial Reporting Standards , Japan Ministry Of Health , Takeda Pharmaceutical Company Limited , Constant Exchange Rate , Costa Saroukos , Free Cash Flow , Rare Hematology , Derived Therapy , Emerging Markets , Rare Diseases , Japan Ministry , Press Release , Willebrand Disease , Brain Cargo , Constant Exchange , Launch Products , Rare Genetic , Plasma Derived Therapies , Pharmaceutical Company Limited , Annual Report , Underlying Revenue , Core Operating Profit , Underlying Core Operating Profit , Core Net Profit , Underlying Core , Net Debt , Noon Buying Rate , New York , Takeda Yakuhin Kogyo ,